Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna and keeping the price target at $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Hold rating due to a combination of factors, primarily revolving around the financial outlook for Moderna. The decision to slightly reduce the Q2 total revenue projection to $120 million from the previous $125 million reflects a cautious stance, largely influenced by lower anticipated revenue from COVID-19 related products.
Despite these adjustments, the unadjusted GAAP EPS forecast remains steady at ($2.90), indicating that the financial expectations for the company have not drastically changed. The price target is maintained at $30, reinforcing the Hold rating as the stock is perceived to be fairly valued under current market conditions.
Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Regeneron. According to TipRanks, Van Buren has an average return of -1.4% and a 44.07% success rate on recommended stocks.
In another report released on July 11, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $35.00 price target.